Efficacy and Safety of Transurethral Columnar Balloon Dilation of the Prostate for the Treatment of Benign Prostatic Hyperplasia: A Multicenter Trial
Table 2
Comparison of benign prostatic hyperplasia related indicators in patients before and after surgery.
IPSS
QoL
Qmax
PVR
IIEF-5
MSHQ-EjD-SF
Presurgery
21.47 (16-32)
4.54 (3-6)
8.91 (3.56-14.36)
180.69 (105.12-255.88)
20.96 (13-25)
10.47 (8-13)
1 month
18.94 (12-31)
3.99 (1-6)
11.20 (4.97-17.43)
158.37 (76.27-238.99)
21.46 (14-26)
10.50 (8-15)
3 months
20.92 (13-33)
4.08 (2-6)
13.58 (6.40-20.37)
135.99 (50.27-222.67)
21.96 (14-26)
11.46 (8-16)
6 months
22.54 (14-35)
4.89 (3-6)
15.81 (8.12-22.73)
113.55 (15.69-206.72)
21.67 (13-27)
11.09 (6-16)
12 months
25.96 (16-37)
4.62 (2-6)
18.11 (10.02-25.48)
91.32 (2.97-187.46)
21.42 (12-27)
10.93 (6-16)
Last follow-up
24.98 (16-37)
4.77 (1-6)
19.10 (11.35-26.68)
99.71 (10.82-194.99)
21.3 (12-28)
10.65 (5-17)
Changes from presurgery
+16.35
+5.51
+115.49
-44.82
+1.91
+1.72
≤0.001
≤0.001
≤0.001
≤0.001
≤0.001
≤0.001
Note: QoL: quality of life; Qmax: maximum urinary flow rate; PVR: Postvoid Residual Urine Volume; IIEF-5: International Index of Erectile Function; MSHQ-EjD-SF: Male Sexual Health Questionnaire-Ejaculatory Dysfunction Short Form.
